

INNOVATORS WITH

COMMERCIAL EXPERTISE

We discover, develop, commercialize and secure coverage for practice-changing tests

[LEARN MORE](#)

Cutaneous Melanoma

Our genomic test was found to identify metastatic risk in Stage 1 & 2 melanoma independent of sentinel lymph node biopsy status and other traditional staging factors.

[DecisionDx-Melanoma](#)

Uveal Melanoma

This gene expression profile test quickly became standard of care based on its ability to accurately identify aggressive metastatic disease in this rare and deadly eye cancer.

[DecisionDx-UM](#)[ORDER A TEST](#)

NEWS

5.7.2019

Castle Biosciences' Cutaneous Squamous Cell Carcinoma Prognostic Test Development Update Presented at the American College of Mohs Surgery Annual Meeting

Friendswood, TX – May 7, 2019 – Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to ... [READ MORE](#)

4.24.2019

Castle Biosciences Receives 2019 Technology Innovation in Melanoma Award from American Skin Association

Friendswood, TX – April 24, 2019 – Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to ... [READ MORE](#)

CASTLE
BIOSCIENCES INCORPORATED



Customer Service
866-788-9007

contact@castlebiosciences.com

Company

[About Us](#)
[Management](#)
[Board of Directors](#)
[Investors](#)
[Licenses](#)
[Contact Us](#)

Tests

[Cutaneous Melanoma](#)
[Uveal Melanoma](#)

Research & Development

[Our Approach](#)
[Tests in Development](#)
[Publications](#)

Clinician Services

[Order a Test](#)
[Insurance Coverage](#)
[Physician Login](#)

Patient Resources

[Overview](#)
[Patient FAQ](#)
[Insurance Coverage](#)

News & Information

[Press Releases and Media](#)
[Publications](#)
[Email Alerts](#)